Clinical Trials Logo

Refractory Lymphoma clinical trials

View clinical trials related to Refractory Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04994626 Not yet recruiting - Relapse Clinical Trials

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Ibrutinib Combined With Rituximab in Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies.